Evidence map›Paper›PMID 34261490›Full record

ArticleMicrobial cell factories2021

Expression of antibody fragments in Saccharomyces cerevisiae strains evolved for enhanced protein secretion.

Yanyan Wang, Xiaowei Li, Xin Chen, Jens Nielsen, Dina Petranovic, Verena Siewers

Open access · goldAbstract read
In one paragraph

Article in Microbial cell factories, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Engineered Antibodies as Cancer Radiotheranostics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Review
  9. Microorganisms · 2024
    Review
  10. Review
  11. Review
  12. Article
  13. NANOBODIES®: A Review of Diagnostic and Therapeutic ApplicationsInternational journal of molecular sciences · 2023
    Review
  14. Article
  15. Review
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Yanyan WangDepartment of Biology and Biological Engineering, Chalmers University of Technology, Gothenburg, Sweden.
Xiaowei LiDepartment of Biology and Biological Engineering, Chalmers University of Technology, Gothenburg, Sweden.
Xin ChenDepartment of Biology and Biological Engineering, Chalmers University of Technology, Gothenburg, Sweden.ORCID https://orcid.org/0000-0003-2788-1314
Jens NielsenDepartment of Biology and Biological Engineering, Chalmers University of Technology, Gothenburg, Sweden.
Dina PetranovicDepartment of Biology and Biological Engineering, Chalmers University of Technology, Gothenburg, Sweden.
Verena SiewersDepartment of Biology and Biological Engineering, Chalmers University of Technology, Gothenburg, Sweden. siewers@chalmers.se.ORCID http://orcid.org/0000-0002-9502-9804
Chalmers University of Technology · SENovo Nordisk Foundation · DK

Funding

EPA EP-D-16-017
6 · The paper itself

Abstract

Monoclonal antibodies, antibody fragments and fusion proteins derived thereof have revolutionized the practice of medicine. Major challenges faced by the biopharmaceutical industry are however high production costs, long processing times and low productivities associated with their production in mammalian cell lines. The yeast Saccharomyces cerevisiae, a well-characterized eukaryotic cell factory possessing the capacity of post-translational modifications, has been industrially exploited as a secretion host for production of a range of products, including pharmaceuticals. However, due to the incompatible surface glycosylation, few antibody molecules have been functionally expressed in S. cerevisiae. Here, three non-glycosylated antibody fragments from human and the Camelidae family were chosen for expression in a S. cerevisiae strain (HA) previously evolved for high α-amylase secretion. These included the Fab fragment Ranibizumab (Ran), the scFv peptide Pexelizumab (Pex), and a nanobody consisting of a single V-type domain (Nan). Both secretion and biological activities of the antibody fragments were confirmed. In addition, the secretion level of each protein was compared in the wild type (LA) and two evolved strains (HA and MA) with different secretory capacities. We found that the secretion of Ran and Nan was positively correlated with the strains' secretory capacity, while Pex was most efficiently secreted in the parental strain. To investigate the mechanisms for different secretion abilities in these selected yeast strains for the different antibody fragments, RNA-seq analysis was performed. The results showed that several bioprocesses were significantly enriched for differentially expressed genes when comparing the enriched terms between HA.Nan vs. LA.Nan and HA.Pex vs. LA.Pex, including amino acid metabolism, protein synthesis, cell cycle and others, which indicates that there are unique physiological needs for each antibody fragment secretion.

Indexed as

Gene ExpressionAntibodies, Monoclonal, HumanizedGlycosylationProtein Processing, Post-TranslationalProtein TransportRanibizumabSaccharomyces cerevisiaeSaccharomyces cerevisiae ProteinsSingle-Chain AntibodiesSingle-Domain AntibodiesAntibodies, Monoclonal, HumanizedpexelizumabRanibizumabSaccharomyces cerevisiae ProteinsSingle-Chain AntibodiesSingle-Domain AntibodiesPharmaceutical proteinsProtein secretion capacityRNA-seq analysisSaccharomyces cerevisiae

Identifiers

PMID34261490
PMCPMC8278646
OpenAlexW3182298817

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.